OBJECTIVE: The objective of this study was to evaluate a depression-focused treatment for smoking cessation in pregnant women versus a time and contact health education control. We hypothesized that the depression-focused treatment would lead to improved abstinence and reduced depressive symptoms among women with high levels of depressive symptomatology. No significant main effects of treatment were hypothesized. METHOD:Pregnant smokers (N = 257) were randomly assigned to a 10-week, intensive, depression-focused intervention (cognitive behavioral analysis system of psychotherapy; CBASP) or to a time and contact control focused on health and wellness (HW); both included equivalent amounts of behavioral and motivational smoking cessation counseling. Of the sample, 54% were African American, and 37% met criteria for major depression. Mean age was 25 years (SD = 5.9), and women averaged 19.5 weeks (SD = 8.5) gestation at study entry. We measured symptoms of depression using the Center for Epidemiological Studies-Depression Scale (Radloff, 1977). RESULTS: At 6 months posttreatment, women with higher levels of baseline depressive symptoms treated with CBASP were abstinent significantly more often, F(1, 253) = 5.61, p = .02, and had less depression, F(1, 2620) = 10.49, p = .001, than those treated with HW; those with low baseline depression fared better in HW. Differences in abstinence were not retained at 6 months postpartum. CONCLUSIONS: The results suggest that pregnant women with high levels of depressive symptoms may benefit from a depression-focused treatment in terms of improved abstinence and depressive symptoms, both of which could have a combined positive effect on maternal and child health.
RCT Entities:
OBJECTIVE: The objective of this study was to evaluate a depression-focused treatment for smoking cessation in pregnant women versus a time and contact health education control. We hypothesized that the depression-focused treatment would lead to improved abstinence and reduced depressive symptoms among women with high levels of depressive symptomatology. No significant main effects of treatment were hypothesized. METHOD: Pregnant smokers (N = 257) were randomly assigned to a 10-week, intensive, depression-focused intervention (cognitive behavioral analysis system of psychotherapy; CBASP) or to a time and contact control focused on health and wellness (HW); both included equivalent amounts of behavioral and motivational smoking cessation counseling. Of the sample, 54% were African American, and 37% met criteria for major depression. Mean age was 25 years (SD = 5.9), and women averaged 19.5 weeks (SD = 8.5) gestation at study entry. We measured symptoms of depression using the Center for Epidemiological Studies-Depression Scale (Radloff, 1977). RESULTS: At 6 months posttreatment, women with higher levels of baseline depressive symptoms treated with CBASP were abstinent significantly more often, F(1, 253) = 5.61, p = .02, and had less depression, F(1, 2620) = 10.49, p = .001, than those treated with HW; those with low baseline depression fared better in HW. Differences in abstinence were not retained at 6 months postpartum. CONCLUSIONS: The results suggest that pregnant women with high levels of depressive symptoms may benefit from a depression-focused treatment in terms of improved abstinence and depressive symptoms, both of which could have a combined positive effect on maternal and child health.
Authors: R A Brown; C W Kahler; R Niaura; D B Abrams; S D Sales; S E Ramsey; M G Goldstein; E S Burgess; I W Miller Journal: J Consult Clin Psychol Date: 2001-06
Authors: Elyse R Park; Yuchiao Chang; Virginia Quinn; Susan Regan; Lee Cohen; Adele Viguera; Christina Psaros; Kaile Ross; Nancy Rigotti Journal: Nicotine Tob Res Date: 2009-05-12 Impact factor: 4.244
Authors: Sarah M Wilson; Amie R Newins; Alyssa M Medenblik; Nathan A Kimbrel; Eric A Dedert; Terrell A Hicks; Lydia C Neal; Jean C Beckham; Patrick S Calhoun Journal: Womens Health Issues Date: 2018-07-27
Authors: Rina D Eiden; Kenneth E Leonard; Craig R Colder; Gregory G Homish; Pamela Schuetze; Teresa R Gray; Marilyn A Huestis Journal: J Stud Alcohol Drugs Date: 2011-11 Impact factor: 2.582
Authors: Jerry M Suls; Tana M Luger; Susan J Curry; Robin J Mermelstein; Amy K Sporer; Larry C An Journal: Am J Prev Med Date: 2012-06 Impact factor: 5.043
Authors: Janice A Blalock; Nisha Nayak; David W Wetter; Lisa Schreindorfer; Jennifer A Minnix; Jennifer Canul; Paul M Cinciripini Journal: Psychol Addict Behav Date: 2011-09-19
Authors: Van T Tong; Sherry L Farr; Jennifer Bombard; Denise DʼAngelo; Jean Y Ko; Lucinda J England Journal: Obstet Gynecol Date: 2016-09 Impact factor: 7.661
Authors: Michele D Levine; Yu Cheng; Marsha D Marcus; Melissa A Kalarchian; Rebecca L Emery Journal: JAMA Intern Med Date: 2016-04 Impact factor: 21.873